Workflow
Neurogene(NGNE) - 2021 Q2 - Quarterly Report
NGNENeurogene(NGNE)2021-08-05 20:15

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 __________________________________________________ For the transition period from ________ to ________ Commission file number: 001-36327 __________________________________________________ Neoleukin Therapeutics, Inc. (Exact name of registrant as specified in its charter) __________________________________________________ Delaware 98-0542593 (State or other jurisdiction of incorporation or organization) FORM 10-Q __________________________ ...